Concurrent atrial fibrillation (AF) in patients requiring P2Y12 inhibitor therapy also poses a conundrum in balancing bleeding risk with the combination of DOACs to prevent cerebrovascular events. This evidence concerns the gene P2RY12 and atrial fibrillation.